Published in Hepatology on January 01, 2012
Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine (2015) 0.76
Expression of transforming growth factor β1 promotes cholangiocarcinoma development and progression. Cancer Lett (2016) 0.75
Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma. Heliyon (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science (1993) 19.80
Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity (1998) 5.75
Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol (2005) 5.09
Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol (2004) 4.39
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med (1994) 3.66
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Functional expression of the costimulatory molecule, B7/BB1, on murine dendritic cell populations. J Exp Med (1992) 2.79
Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg (2001) 2.57
The MRC OX-62 antigen: a useful marker in the purification of rat veiled cells with the biochemical properties of an integrin. J Exp Med (1992) 2.24
Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol (2003) 1.80
Regulation of bioactive IL-12 production in lipopolysaccharide-stimulated human monocytes is determined by the expression of the p35 subunit. J Immunol (1996) 1.74
Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology (2006) 1.64
A novel "patient-like" model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology (2008) 1.53
Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest (1996) 1.43
Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol (2005) 1.33
erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology (2005) 1.26
Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res (2000) 1.26
cDNA cloning and expression of bovine aspartyl (asparaginyl) beta-hydroxylase. J Biol Chem (1992) 1.19
Absence of post-translational aspartyl beta-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. J Biol Chem (2001) 1.15
Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab Invest (2002) 1.12
Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery (2007) 1.07
Analysis of maturation states of rat bone marrow-derived dendritic cells using an improved culture technique. Histochem Cell Biol (2002) 1.02
Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev (2004) 1.01
Partial purification and characterization of bovine liver aspartyl beta-hydroxylase. J Biol Chem (1990) 1.00
Two phenotypically distinct subsets of spleen dendritic cells in rats exhibit different cytokine production and T cell stimulatory activity. J Immunol (2002) 1.00
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration. Mol Cancer Res (2010) 0.98
Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival. Ann Surg (2010) 0.94
Cloning and characterization of the human gene encoding aspartyl beta-hydroxylase. Gene (1994) 0.93
Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. Gastroenterology (2006) 0.93
A fully active catalytic domain of bovine aspartyl (asparaginyl) beta-hydroxylase expressed in Escherichia coli: characterization and evidence for the identification of an active-site region in vertebrate alpha-ketoglutarate-dependent dioxygenases. Proc Natl Acad Sci U S A (1994) 0.93
Prognostic value of humbug gene overexpression in stage II colon cancer. Hum Pathol (2006) 0.92
Aspartyl beta-hydroxylase: in vitro hydroxylation of a synthetic peptide based on the structure of the first growth factor-like domain of human factor IX. Proc Natl Acad Sci U S A (1989) 0.91
Immature CD4- CD103+ rat dendritic cells induce rapid caspase-independent apoptosis-like cell death in various tumor and nontumor cells and phagocytose their victims. J Immunol (2005) 0.90
Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol (2009) 0.90
Human aspartyl (asparaginyl) beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas (2002) 0.88
Generation and characterization of an immunogenic dendritic cell population. J Immunol Methods (2008) 0.86
Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis (2005) 3.78
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy. Hepatology (2010) 2.14
Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis (2005) 2.12
Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis (2005) 2.11
Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol (2008) 1.97
Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology (2004) 1.88
Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis (2006) 1.82
Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol (2003) 1.80
Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. Alcohol Clin Exp Res (2010) 1.77
Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology (2014) 1.76
The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res (2008) 1.71
Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis (2006) 1.65
Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology (2006) 1.64
Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol (2008) 1.56
ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology (2002) 1.54
Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci (2006) 1.50
Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology (2006) 1.49
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. Hepatology (2009) 1.49
Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis (2006) 1.48
Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology (2006) 1.44
Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol (2013) 1.40
Expression of uncoupling protein-2 in human colon cancer. Clin Cancer Res (2004) 1.37
Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol (2005) 1.33
Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer (2003) 1.32
Acute ethanol exposure inhibits insulin signaling in the liver. Hepatology (2007) 1.31
The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res (2004) 1.30
Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology (2005) 1.30
Insulin resistance in experimental alcohol-induced liver disease. J Gastroenterol Hepatol (2008) 1.28
Prevention of hepatocellular carcinoma. N Engl J Med (2004) 1.27
erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer. Gastroenterology (2005) 1.26
Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. Hepatology (2003) 1.26
Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. Hepatology (2004) 1.24
Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology (2011) 1.23
Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol Clin Exp Res (2007) 1.23
Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol (2006) 1.22
Alcohol-induced disruption of endocrine signaling. Alcohol Clin Exp Res (2007) 1.21
Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs (2009) 1.21
PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol (2009) 1.20
Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res (2012) 1.19
Acute and chronic alcohol abuse modulate immunity. Alcohol Clin Exp Res (2006) 1.18
Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev (2010) 1.18
Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol (2012) 1.16
Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis (2009) 1.15
Modulation of hepatitis B virus secretion by naturally occurring mutations in the S gene. J Virol (2004) 1.13
Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab Invest (2002) 1.12
Hepatitis C virus and alcohol. Semin Liver Dis (2009) 1.08
Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease. J Hepatol (2010) 1.07
Lack of UCP2 reduces Fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression. Hepatology (2006) 1.07
Insulin resistance, ceramide accumulation, and endoplasmic reticulum stress in human chronic alcohol-related liver disease. Oxid Med Cell Longev (2012) 1.07
Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimers Dis (2009) 1.07
A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology (2010) 1.06
Ethanol impaired neuronal migration is associated with reduced aspartyl-asparaginyl-beta-hydroxylase expression. Acta Neuropathol (2008) 1.06
Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral promoters in hepatic and nonhepatic cell lines. Virology (2003) 1.06
Chronic ethanol consumption impairs cellular immune responses against HCV NS5 protein due to dendritic cell dysfunction. Gastroenterology (2006) 1.04
Differential growth factor regulation of aspartyl-(asparaginyl)-beta-hydroxylase family genes in SH-Sy5y human neuroblastoma cells. BMC Cell Biol (2006) 1.04
Ethanol inhibition of aspartyl-asparaginyl-beta-hydroxylase in fetal alcohol spectrum disorder: potential link to the impairments in central nervous system neuronal migration. Alcohol (2009) 1.04
Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology (2003) 1.03
A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res (2010) 1.02
Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol (2010) 1.02
Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology (2004) 1.02
Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma. Cancer Detect Prev (2004) 1.01
Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology (2009) 1.01
Tie2 vascular endothelial receptor expression and function in hepatocellular carcinoma. Hepatology (2002) 1.01
Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol Cancer Ther (2003) 1.00
The liver-brain axis of alcohol-mediated neurodegeneration: role of toxic lipids. Int J Environ Res Public Health (2009) 1.00
Hepatitis C virus NS2 protein triggers endoplasmic reticulum stress and suppresses its own viral replication. J Hepatol (2010) 0.99
Role of aspartyl-(asparaginyl) beta-hydroxylase in placental implantation: Relevance to early pregnancy loss. Hum Pathol (2006) 0.99
Limited therapeutic effect of N-acetylcysteine on hepatic insulin resistance in an experimental model of alcohol-induced steatohepatitis. Alcohol Clin Exp Res (2011) 0.98
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration. Mol Cancer Res (2010) 0.98
Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection. PLoS One (2012) 0.97
Uncoupling protein-2 modulates the lipid metabolic response to fasting in mice. Am J Physiol Gastrointest Liver Physiol (2008) 0.96
The p85beta regulatory subunit of PI3K serves as a substrate for PTEN protein phosphatase activity during insulin mediated signaling. Biochem Biophys Res Commun (2010) 0.96
Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma. J Hepatol (2010) 0.94
Insulin and insulin-like growth factor resistance in alcoholic neurodegeneration. Alcohol Clin Exp Res (2008) 0.94
Enhanced colon tumor induction in uncoupling protein-2 deficient mice is associated with NF-kappaB activation and oxidative stress. Carcinogenesis (2006) 0.94
Low density contrast agents for x-ray phase contrast imaging: the use of ambient air for x-ray angiography of excised murine liver tissue. Phys Med Biol (2008) 0.94
Aspartyl-(asparaginyl) beta-hydroxylase, hypoxia-inducible factor-alpha and Notch cross-talk in regulating neuronal motility. Oxid Med Cell Longev (2010) 0.94
ATP luminescence-based motility-invasion assay. Biotechniques (2002) 0.94
Rat strain differences in susceptibility to alcohol-induced chronic liver injury and hepatic insulin resistance. Gastroenterol Res Pract (2010) 0.94
A cell-surface β-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology (2014) 0.94
Peroxisome proliferator-activated receptor agonist treatment of alcohol-induced hepatic insulin resistance. Hepatol Res (2011) 0.93
Vaccination with protein-transduced dendritic cells elicits a sustained response to hepatitis C viral antigens. Gastroenterology (2006) 0.93
Chimeric constructs between two hepatitis B virus genomes confirm transcriptional impact of core promoter mutations and reveal multiple effects of core gene mutations. Virology (2009) 0.93
Novel organotypic culture model of cholangiocarcinoma progression. Hepatol Res (2012) 0.92
Prognostic value of humbug gene overexpression in stage II colon cancer. Hum Pathol (2006) 0.92
Nanomaterials for X-ray imaging: gold nanoparticle enhancement of X-ray scatter imaging of hepatocellular carcinoma. Nano Lett (2011) 0.92
PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res Treat (2015) 0.91
Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. J Alzheimers Dis (2010) 0.91
Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma. Liver Int (2013) 0.91
Targeting PDGFR-β in Cholangiocarcinoma. Liver Int (2011) 0.91
Insulin resistance, ceramide accumulation and endoplasmic reticulum stress in experimental chronic alcohol-induced steatohepatitis. Alcohol Alcohol (2012) 0.91
Mechanisms of alcohol-induced tissue injury. Alcohol Clin Exp Res (2003) 0.91
Insulin signaling through insulin receptor substrate 1 and 2 in normal liver development. Gastroenterology (2003) 0.91
Induction of angiopoietin-2 gene expression by COX-2: a novel role for COX-2 inhibitors during hepatocarcinogenesis. J Hepatol (2005) 0.90
Differential gene expression profiling of cultured neu-transformed versus spontaneously-transformed rat cholangiocytes and of corresponding cholangiocarcinomas. Exp Mol Pathol (2010) 0.90
Prognostic value of aspartyl (asparaginyl)-beta-hydroxylase/humbug expression in non-small cell lung carcinoma. Hum Pathol (2009) 0.90
Identification of T-cell factor-4 isoforms that contribute to the malignant phenotype of hepatocellular carcinoma cells. Exp Cell Res (2011) 0.89
Glycine decarboxylase mediates a postbinding step in duck hepatitis B virus infection. J Virol (2004) 0.89